Evaluation of exclusive enteral nutrition and corticosteroid induction treatment in new-onset moderate-to-severe luminal paediatric Crohn’s disease

Maria M. E. Jongsma1, Stephanie A. Vuijk1, Martinus A. Cozijnsen1, Merel van Pieterson1, Obbe F. Norbruis2, Michael Groeneweg3, Victorien M. Wolters4, Herbert M. van Wering5, Iva Hojsak6, Kaija-Leena Kolho7,8, Michiel P. van Wijk9, Sarah T. A. Teklenburg-Roord2, Tim G. J. de Meij9, Johanna C. Escher1, Lissy de Ridder1

Received: 30 November 2021 / Revised: 7 April 2022 / Accepted: 2 May 2022 / Published online: 8 June 2022
© The Author(s) 2022

Abstract
To induce remission in luminal paediatric Crohn’s disease (CD), the ESPGHAN/ECCO guideline recommends treatment with exclusive enteral nutrition (EEN) or oral corticosteroids. In newly diagnosed moderate-to-severe paediatric CD patients, we determined the proportion of patients in which EEN or corticosteroids induced remission and maintained remission on azathioprine monotherapy. We included patients from the “TISKids” study assigned to the conventional treatment arm. Patients were aged 3–17 years and had new-onset, untreated luminal CD with weighted paediatric CD activity index (wPCDAI) > 40. Induction treatment consisted of EEN or oral corticosteroids; all received azathioprine maintenance treatment from start of treatment. The primary outcome of this study was endoscopic remission defined as a SES-CD score < 3 without treatment escalation at week 10. Secondary outcomes included proportion of patients without treatment escalation at week 52. In total, 27/47 patients received EEN and 20/47 corticosteroids. At baseline, patient demographics and several inflammation parameters were similar between the two treatment groups. At 10 weeks, clinical remission rates were 7/23 (30%) for EEN and 7/19 (37%) for corticosteroids (p = 0.661). Twenty-nine of 47 consented to endoscopy at 10 weeks, showing endoscopic remission rates without treatment escalation in 2/16 (13%) of EEN-treated patients and in 1/13 (8%) of corticosteroid-treated patients (p = 1.00). At week 52, 23/27 (85%) EEN-treated patients received treatment escalation (median 14 weeks) and 13/20 (65%) corticosteroid-treated patients (median 27 weeks), p = 0.070.

Conclusion: In children with moderate-to-severe newly diagnosed CD, induction treatment with EEN or CS regularly is insufficient to achieve endoscopic remission without treatment escalation at week 10. Trial registration number: NCT02517684

What is Known:
- Endoscopic remission is associated with a low risk of disease progression.
- FL-IFX was superior to conventional treatment in achieving and maintaining remission in paediatric patients with moderate-to-severe CD the first year from diagnosis.

What is New:
- In children with newly diagnosed moderate-to-severe CD, clinical remission rates and endoscopic remission rates without treatment escalation at week 10 were 30% and 13% after EEN and 37% and 8% after corticosteroid induction treatment.
- The current treatment target was often not achieved by either EEN or corticosteroid induction treatment after bridging to azathioprine.

Keywords Mucosal healing · Endoscopic remission · Inflammatory bowel disease · Child · Adolescent · Crohn’s disease

Abbreviations
AZA Azathioprine
CD Crohn’s disease
ECCO European Crohn’s and Colitis Organisation
ESPGHAN European Society for Paediatric Gastroenterology, Hepatology and Nutrition
EEN Exclusive enteral nutrition

Communicated by Peter de Winter

Lissy de Ridder
l.deridder@erasmusmc.nl

Extended author information available on the last page of the article
Introduction

Crohn’s disease (CD) is a chronic inflammatory disease which may affect the entire gastrointestinal tract [1]. Up to one in ten patients is diagnosed during childhood [2]. In the last decade, the treatment goal for paediatric CD patients has changed from control of symptoms to a “treat-to-target” strategy, aiming at endoscopic remission with a higher chance of significantly improving the disease course. Achievement of endoscopic remission is associated with a low risk of disease progression [3]. Timely and individualized interventions are crucial to reduce inflammation and thus prevent irreversible bowel damage and complications [4]. For children with uncomplicated luminal CD, the start of conventional treatment, involving exclusive enteral nutrition (EEN) or oral corticosteroids to induce remission, combined with azathioprine (AZA) to maintain remission, is recommended according to the current European Crohn’s and Colitis Organisation (ECCO)/European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) guideline (2020) [5].

In these patients, EEN and oral corticosteroids have proven to be equally effective in inducing clinical remission [6]. While the mechanism of action of EEN is not yet fully understood, EEN is known to have a direct anti-inflammatory effect on the intestine in patients with CD [7]. However, the 6–8 week period of complete liquid formula, with no other food or drinks allowed, is hard to comply with. On the other hand, oral corticosteroid treatment has a high risk of side effects, such as increased infection rate, Cushingoid appearance, bone demineralization, and growth retardation [8].

In the TISKids randomized controlled trial, it has been shown that in paediatric patients with newly diagnosed moderate-to-severe CD, induction treatment with first-line infliximab (FL-IFX) was superior to conventional treatment in achieving and maintaining remission and linear growth in the first year from diagnosis [9].

Still, EEN and oral corticosteroids are widely used to induce remission in paediatric CD. Therefore, the aim of this study is to compare clinical, biochemical, and endoscopic response and remission achieved by EEN or corticosteroids in the population of newly diagnosed moderate-to-severe luminal paediatric CD patients. Moreover, it will be assessed whether AZA maintenance therapy is capable of maintaining remission.

Methods

Procedures

This study was a secondary analysis of the TISKids study [9]; patients receiving conventional treatment per protocol were included. The choice for either EEN or corticosteroids within the conventional treatment group was up to the patient and parents, in accordance with the treating physician. Details of the TISKids study design and protocol were previously published [10]. Conventional treatment consisted of induction treatment with EEN (polymeric feeding for 6–8 weeks after which normal diet was gradually reintroduced within 2–3 weeks) or oral corticosteroids (1 mg/kg prednisolone daily with a maximum of 40 mg for 4 weeks, followed by tapering down 5 mg per week until stop) combined with AZA as maintenance treatment (2–3 mg/kg, once daily) which was started simultaneously with the induction treatment. In case of thiopurine methyl transferase (TPMT) heterozygosity, AZA dosing was halved. AZA metabolites (6-thioguanine nucleotides and 6-methylmercaptopurine) were measured as part of clinical care. 6-TGN levels below < 230 pmol/8 × 10⁸ RBC were considered insufficient [11]. It was advised to check AZA metabolites in case of loss of response to AZA monotherapy. In all centers, the same protocol was followed and compliance of patients was assessed by the dietician and treating physicians as part of regular inflammatory bowel disease (IBD) care.

Changes in treatment could be made according to the physician’s discretion in patients without response, loss of response, or intolerance to treatment. Additional CD-related therapy included initiation of IFX, any course of EEN, and any course of corticosteroids that was additional to the standard treatment described in the previous section.

Data were collected prior to start of induction therapy, at weeks 6, 10, 14, 22, and 52. At each visit, weighted paediatric CD activity index (wPCDAI) was determined [12]; blood was obtained for routine laboratory analysis. Endoscopy (ileocolonoscopy) was performed prior to start of treatment at week 10, and optionally at week 52. During endoscopy, the Simple Endoscopic Score for Crohn’s Disease (SES-CD) was used to evaluate endoscopic remission [13], which was defined as SES-CD score < 3. Endoscopic response was defined as a reduction in SES-CD score by 50%. A single reader, blinded
for both assigned treatment and time point, evaluated and re-scored all endoscopic still images available by using the physician global assessment endoscopy score \([14]\), to check inter-observer variability between paediatric gastroenterologists \((r = 0.689, p < 0.001)\). Faecal samples were collected for faecal calprotectin (fcal) level measurement prior to start of treatment, at week 10, and at week 52. Fcal levels were assessed in the Erasmus Medical Centre with ELISA (CALPRO assay). When fcal samples were missing, fcal levels determined in the local hospital at this time point were used, which accounted for 13\% of all samples. A fcal level < 100 µg/g was defined as biochemical remission \([15]\). Standard deviation scores (SDS) adjusted for sex and age were used to evaluate linear growth. The SDS were calculated based on the Dutch national reference standards for all patients included in the Netherlands and the World Health Organization (WHO) growth reference standards for all patients included in other countries. Target height and target height SDS were calculated \([16]\). The Growth Analyser Research Calculation Tool was used to calculate the SDS based on these references \([17]\).

### Outcomes

#### Primary outcome

The primary outcome of this study was endoscopic remission defined as a SES-CD score < 3 without treatment escalation at week 10.

#### Secondary outcomes

Secondary outcomes included time-to-treatment escalation from start of induction and clinical disease activity scores over time. At week 6, clinical remission rate (wPCRDAI < 12.5) was assessed. At week 10, clinical remission rate and fcal levels were assessed. At week 14, treatment success was assessed, which was defined as clinical remission without treatment escalation. At week 52, the following outcomes were assessed: (1) cumulative corticosteroid use, (2) need for treatment escalation, (3) linear growth, (4) clinical remission rate, (5) endoscopic remission rate, (6) fcal level. In addition, the association between patients’ characteristics at baseline and treatment success at week 14 as well as IFX use at week 52 was evaluated.

### Statistical analysis

Continuous variables were presented as medians and inter-quartile ranges (IQR) and compared with the Mann–Whitney \(U\) test. Categorical variables were presented as absolute frequencies and percentages and compared by the \(X^2\) test or the Fisher exact test. SES-CD scores with a missing ileum subscore due to the endoscopist’s failure to intubate the terminal ileum were included in the analysis to evaluate endoscopic remission. Patients were analyzed according to the treatment group (EEN or prednisolone) they were initially assigned to. Complete clinical disease activity scores were not available for all patients at every visit. Analysis of clinical disease activity was performed on complete scores at each visit. The median fcal levels and SES-CD scores were subject to right censoring. To correct for this, medians of fcal levels and SES-CD scores were calculated using the Kaplan–Meier method, and treatment groups for these outcomes were compared using the log rank test. The time to treatment escalation outcomes were analysed using the Kaplan–Meier method. A paired analysis was performed for the linear growth. A logistic regression analysis was performed to analyse the association between baseline patients’ characteristics with moderate or severe disease, ESR, CRP, and treatment at week 14 and 52.

All analyses were performed based on a significance level of 0.05. Calculations were performed using IBM SPSS Statistics 24.0 (IBM Corp. Armonk, NY). The TISKids trial is registered in ClinicalTrials.gov, number NCT02517684.

### Ethical considerations

Medical-ethical approval was obtained for each site.

### Results

Forty-seven patients received conventional induction treatment per protocol. To induce remission after diagnosis, 27/47 (57\%) patients were treated with EEN, while 20/47 patients (43\%) were treated with oral corticosteroids. Patients’ characteristics at baseline were, except for fcal levels, similar between the two treatment groups. Fcal levels were significantly higher in the EEN group (median 1197 (1033–1661)) compared to those in the corticosteroid group (592 (555–1133), \(p = 0.01\)) (Table 1). Twenty out of 27 (74\%) EEN-treated patients completed the remission induction treatment. EEN was prematurely ended due to insufficient disease response in 5/7 patients and due to low compliance in 2/7 patients (Fig. 1). These patients all received step-up treatment with corticosteroids. Of the patients who completed EEN treatment, the median duration of EEN treatment was 43 days (IQR 42.0–44.0). All 20 patients with corticosteroids completed the induction treatment of median 30 days (IQR 28–34), whereafter the dose was tapered.

### Efficacy of induction treatment

Twenty-nine out of 47 (62\%) patients consented to the endoscopic evaluation per protocol at 10 weeks. Thereof, 5/16 (31\%) EEN-treated patients and 4/13 (31\%) of the corticosteroid-treated patients showed endoscopic remission. Patients were analyzed according to the treatment group (EEN or prednisolone) they were initially assigned to. Complete clinical disease activity scores were not available for all patients at every visit. Analysis of clinical disease activity was performed on complete scores at each visit. The median fcal levels and SES-CD scores were subject to right censoring. To correct for this, medians of fcal levels and SES-CD scores were calculated using the Kaplan–Meier method, and treatment groups for these outcomes were compared using the log rank test. The time to treatment escalation outcomes were analysed using the Kaplan–Meier method. A paired analysis was performed for the linear growth. A logistic regression analysis was performed to analyse the association between baseline patients’ characteristics with moderate or severe disease, ESR, CRP, and treatment at week 14 and 52.
treatment response ($p=0.978$). Endoscopic remission without treatment escalation was found in 2/16 (13%) EEN-treated patients and 1/13 (8%) corticosteroid-treated patients ($p=1.00$). Moreover, one out of 16 patients (6%) in the EEN group did achieve endoscopic remission, but received treatment escalation before 10 weeks. Remarkably, in the group of patients that underwent endoscopy, wPCDAI was significantly lower than in patients in whom repeated endoscopy was not performed (Supplemental Table 1).

### Clinical remission rates

At week 6, 11/25 patients (44%) treated with EEN were in clinical remission, compared to 10/18 patients (56%) patients treated with corticosteroids ($p=0.455$). A decrease of the clinical remission rate was seen at week 10. At week 10, 7/23 patients (30%) EEN and 7/19 (37%) patients treated with corticosteroids were in clinical remission ($p=0.661$). In line with the endoscopic findings, in both groups, only a minority of patients had fecal levels below 100 µg/g (EEN:

### Table 1

| Baseline characteristics of patients treated with exclusive enteral nutrition versus corticosteroids |
|---------------------------------------------------------------|
|                                                                                     |
| **EEN (n = 27)** | **Corticosteroids (n = 20)** | **p value** |
| Age at diagnosis, years | 14.5 (12.4–16.5) | 13.8 (11.6–15.6) | 0.282 |
| Male sex | 16 (59%) | 10 (50%) | 0.528 |
| Height, cm | 164.3 (149.2–175.0) | 157.4 (143.5–16.6) | 0.169 |
| Weight, kg | 48.5 (33.8–56.3) | 41.8 (31.1–53.9) | 0.240 |
| SDS height for age | −0.49 (−1.08 to 0.30) | −0.80 (−1.10 to −0.11) | 0.533 |
| wPCDAI | 60.0 (48.8–67.8) | 53.8 (45.6–81.3) | 0.909 |
| CRP, mg/L | 34.5 (24.7–65.9) | 39.5 (20.5–69.0) | 0.921 |
| ESR, mm/h | 27.0 (17.0–47.5) | 34.0 (22.5–71.0) | 0.091 |
| SES-CD* | 15 (6–22) | 19 (6–28) | 0.275 |
| Leukocytes, 10⁹/L | 8.9 (6.8–11.7) | 9.1 (6.2–11.8) | 0.982 |
| Faecal calprotectin, µg/g | 1197 (1033–1661) | 592 (555–1133) | 0.014 |
| Perianal disease** | 5 (19%) | 4 (20%) | 0.898 |
| Paris classification | < 10 years | 4 (15%) | 3 (15%) | 0.757 |
| | 10–17 years | 20 (74%) | 16 (80%) |
| | 17–40 years | 3 (11%) | 1 (5%) |
| Disease location | L1 | 6 (22%) | 5 (25%) | 0.755 |
| | L2 | 6 (22%) | 6 (35%) |
| | L3 | 15 (56%) | 9 (45%) |
| | Isolated L4 | - | - |
| Upper disease location | No upper GI | 14 (52%) | 11 (55%) | 0.942 |
| | L4a | 12 (44%) | 8 (45%) |
| | L4b | 1 (4%) | 1 (5%) |
| Disease behaviour | B1 | 25 (93%) | 16 (80%) | 0.201 |
| | B2 | 2 (7%) | 4 (20%) |
| | B3 | - | - |
| | B2B3 | - | - |
| Growth delay | 1 (4%) | 1 (5%) | 0.828 |
| Time between diagnostic endoscopy and start of treatment, days | 7 (1–13) | 8 (3–17) | 0.266 |

Data are $n$ (%) or median (IQR). wPCDAI, weighted paediatric Crohn’s disease activity index; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; SES-CD, Simple Endoscopic Score for Crohn’s Disease

*Terminal ileum was not intubated in 6/20 (30%) of the patients treated with corticosteroids and in 6/27 (22%) of the patients treated with EEN ($p=0.545$)

**Perianal disease comprised inactive fistula, skin tags, or anal fissures
3/21 (14%) vs. corticosteroids: 2/16 (13%), \( p = 0.875 \) at week 10. At week 14, five out of 25 (20%) of the EEN-treated patients and 9/19 (47%) of the corticosteroid-treated patients were in clinical remission without treatment escalation after induction treatment (\( p = 0.054 \)). One of these 14 patients switched to methotrexate after 4 weeks due to intolerance of AZA.

**Treatment course**

Overall, if the primary induction treatment was taken into account the total number of days on corticosteroids was median 78 (71–103) days: for the corticosteroid-treated patients, which was significantly more than that in the EEN group (median 54 (0–70) days; \( p < 0.001 \)). Twenty-three out of 27 (85%) EEN-treated patients received treatment escalation after a median of 14 weeks and 13/20 (65%) corticosteroid treated patients after a median of 27 weeks, \( p = 0.067 \) (Fig. 2a). In addition, a similar percentage of patients used IFX at week 52, 16/27 (59%) of EEN-treated patients were escalated to IFX at week 52, while this yielded 13/20 (65%) of the patients treated with corticosteroids (\( p = 0.689 \)) (Fig. 2b).

**One-year follow-up**

At week 52, no significant differences were found between treatment groups in the proportion of patients in clinical, biochemical, and endoscopic remission without treatment escalation at week 52 (Table 2). Out of the 14 patients who achieved treatment success at week 14, 2/5 (40%) of the EEN-treated patients and 4/9 (44%) of the corticosteroid treated patients were in clinical remission without treatment escalation at 52 weeks on AZA monotherapy (\( p = 0.872 \)). In 11/14 (79%) patients, AZA metabolites were assessed. Nine out of 11 (81%) patients had adequate AZA trough levels. One of the 2 patients without adequate 6-TGN levels was not in clinical remission at 52 weeks without treatment escalation.

Surprisingly, SDS height for age decreased significantly in EEN-treated patients (\(-0.49\) to \(-0.64\) (\( p = 0.016 \)), while SDS height for age was stable in corticosteroid-treated patients (\(-0.80\) at baseline to \(-0.86\) (\( p = 0.615 \)) (Table 2). However, in the subgroup of patients who were able to complete EEN induction treatment (\( n = 20 \)), SDS height for age numerically decreased after 52 weeks (\(-0.51\) at baseline to \(-0.65\) after 52 weeks although this difference was not statistically significant (\( p = 0.086 \)). At 52 weeks, SDS height for age was not significantly different between treatment groups (\( p = 0.688 \)). During the first year after diagnosis, in both treatment groups, one patient underwent an ileocecal resection. Three EEN-treated patients received surgery due to a perianal abscess.

**Patients’ characteristics at diagnosis associating with clinical disease outcomes**

In a univariate analysis, moderate clinical disease scores significantly increased the odds of having treatment success at week 14 (OR 5.50 [1.26–23.94], \( p = 0.023 \)) compared to severe clinical disease scores at baseline (Table 3A). In multivariable regression analysis, patients treated with corticosteroids had significantly higher odds of having treatment success at week 14 (OR 5.49 [1.13–26.62], \( p = 0.035 \)) compared to EEN, irrespective of having moderate or severe clinical disease scores at diagnosis (Table 3B). None of the patient characteristics at baseline was significantly associated with IFX use within 1 year (Table 3A and 3C).
Fig. 2  A Kaplan-Meier estimates of the time to treatment escalation after start of therapy. Any additional CD-related therapy or surgery during the 52 weeks was considered treatment escalation. B Proportion of patients receiving each treatment option from 6 weeks onwards, depicted per treatment group. EEN, exclusive enteral nutrition; CS, corticosteroids; IFX, infliximab; AZA, azathioprine
Table 2  Findings at week 52 per treatment group

|                               | EEN (n = 27) | Corticosteroids (n = 20) | p-value |
|-------------------------------|--------------|--------------------------|---------|
| wPCDAI, median (IQR)          | 4 (0–14)     | 11 (0–28)                | 0.158   |
| Clinical remission (wPCDAI < 12.5) | 14/23 (61%)  | 9/18 (50%)               | 0.486   |
| Endoscopic remission, n (%)*  | 2/6 (33%)    | 3/7 (43%)                | 0.587   |
| SES-CD, median (IQR)**        | 3 (0–6)      | 4 (1–7)                  | 0.838   |
| Fcal < 100 µg/g, n (%)        | 5/17 (29%)   | 3/13 (23%)               | 0.697   |
| SDS height for age, median (IQR) | −64 (−97 to 0.10) | −86 (−1.3 to 0.19) | 0.688   |

Clinical remission is defined as a wPCDAI < 12.5. Endoscopic remission was defined as a SES-CD < 3
wPCDAI weighted paediatric Crohn’s disease activity index (range 0–125), SES-CD Simple Endoscopic Score for Crohn’s Disease (range 0–60), Fcal, faecal calprotectin level
*6 EEN patients and 7 prednisolone-treated patients consented for endoscopy at week 52. Baseline characteristics of these patients are similar
**Terminal ileum was not intubated in 1/7 (14%) of the patients treated with corticosteroids and in 2/6 (33%) of the patients treated with EEN (p=0.559)

Table 3  Association of patients’ characteristics with sustained remission at week 14 and IFX use at week 52. A: Univariate analysis of associations with patients’ characteristics and treatment success at week 14 and IFX use at week 52. B: Multivariate analysis for associations with treatment success at week 14. C: Multivariable analysis for associations with IFX use at week 52. For categorical covariates, the last category (severe disease, EEN treatment) was the reference category. Moderate disease, wPCDAI 40–57.5; Severe disease, wPCDAI > 57.5; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; Fcal, faecal calprotectin level

3A

|                                      | Treatment success at week 14 Odds ratio [95% CI] | p-value | IFX use at week 52 Odds ratio [95% CI] | p-value |
|--------------------------------------|--------------------------------------------------|---------|--------------------------------------|---------|
| Corticosteroid or EEN treatment      | 3.60 [0.95–13.62]                                 | 0.059   | 1.28 [0.39–4.23]                     | 0.689   |
| Disease location at diagnosis        | 1.44 (0.63–3.29)                                  | 0.386   | 0.87 [0.42–1.80]                     | 0.708   |
| Moderate or severe disease at diagnosis | 5.50 [1.26 – 23.94]                                | 0.023   | 0.52 [0.16 – 1.71]                   | 0.280   |
| SES-CD at diagnosis                  | 1.01 [0.94–1.09]                                  | 0.784   | 1.01 [0.94–1.08]                     | 0.821   |
| Albumin at diagnosis                 | 1.02 [0.96–1.08]                                  | 0.571   | 0.94 [0.85–1.04]                     | 0.252   |
| ESR at diagnosis                     | 0.97 [0.93 – 1.00]                                | 0.049   | 1.01 [0.98–1.04]                     | 0.510   |
| CRP at diagnosis                     | 0.98 [0.96 – 1.01]                                | 0.113   | 1.01 [0.99 – 1.03]                   | 0.377   |
| Fcal at diagnosis                    | 1.00 [1.00–1.00]                                  | 0.296   | 1.00 [1.00–1.00]                     | 0.659   |

3B

|                                      | Odds ratio [95% CI] | p-value |
|--------------------------------------|---------------------|---------|
| Moderate or severe disease at diagnosis | 2.69 [0.46 – 15.65] | 0.271   |
| ESR at diagnosis                     | 0.97 [0.94–1.01]    | 0.110   |
| CRP at diagnosis                     | 0.99 [0.96–1.02]    | 0.548   |
| Corticosteroid or EEN treatment      | 5.49 [1.13–26.62]   | 0.035   |

3C

|                                      | Odds ratio [95% CI] | p-value |
|--------------------------------------|---------------------|---------|
| Moderate or severe disease at diagnosis | 0.61 [0.15–2.47]   | 0.484   |
| ESR at diagnosis                     | 1.00 [0.97–1.03]    | 0.991   |
| CRP at diagnosis                     | 1.01 [0.99–1.03]    | 0.575   |
| Corticosteroid or EEN treatment      | 1.47 [0.40–5.32]    | 0.560   |
Discussion

In the majority of children with newly diagnosed moderate-to-severe CD, EEN or corticosteroid induction treatment bridging to AZA monotherapy according to ECCO-ESPGHAN guideline [5] is insufficient to reach the target of endoscopic remission. At 10 weeks, our rates of endoscopic remission without treatment escalation after induction with EEN or corticosteroid induction were lower than <15% in both groups. This was an unexpected finding, and lower than reported in previously published studies [7, 18–21], particularly for the children treated with EEN [22]. However, patients in most of these studies had lower disease activity at baseline compared to the patients included in our study [7, 19–22]. This does not fully account for the study of Borrelli et al., which mostly included patients with moderate-to-severe CD [18]. In this study, endoscopic remission at 10 weeks was reported in 74% of patients treated with EEN, and in 33% of those treated with corticosteroids. There are several hypotheses to explain the low endoscopic remission rates we observed. First, a difference in definition of endoscopic remission was used. In this study endoscopic remission has been defined as SES-CD < 3 following the definition of mucosal healing [13]. This was stricter than a decrease in the endoscopic score of at least 50% relative to baseline used by Borrelli et al. [18, 23]. However, using the same definition, the number of patients with response in our cohort still would have been lower in the EEN group (31%), while in corticosteroid-treated patients achieving this endpoint was comparable to the Borrelli cohort (31%).

Second, we stopped EEN after median of 6 weeks whereas patients in the Borrelli cohort were treated for 10 weeks with EEN until endoscopy. This may suggest that children with moderate-to-severe CD may have higher endoscopic remission rates if they receive EEN treatment for a longer period (i.e., more than 6 weeks). This argument does not hold for the patients treated with corticosteroids. At 10 weeks, they were mostly still tapering corticosteroids. Third, in the 4 weeks after EEN was stopped, disease activity may have flared rapidly, including the rise of fecal levels, and remission may have been lost [24]. This last explanation implies patients may actually have achieved endoscopic remission after induction treatment with EEN, but endoscopic remission was not sustained after re-introduction of their normal diet.

Although there are several explanations for these unexpected results, our results show that when children are treated following the recently revised guidelines [5], treatment targets to induce and maintain remission are not achieved in the majority of the children with moderate-to-severe CD.

Surprisingly, the EEN-treated patients in our study decreased in linear growth during the year following EEN induction treatment [25, 26]. Despite that this could be partially caused by inherent variability of the length and weight measurements, we have proposed some possible explanations for this finding. In 19% of the patients, EEN induction treatment was prematurely stopped due to lack of response. Moreover, almost half of the patients received treatment escalation before week 14. This indicates that patients still had active disease, which may have a negative impact on linear growth [27]. Another factor which may have contributed to growth delay is the fact that 56% of EEN-treated patients received corticosteroids within 52 weeks [8]. This advocates, in line with previous studies, that a maximally effective therapy from diagnosis onwards is highly desired [4].

After induction of remission, AZA monotherapy was continued to maintain remission. It may take up to 16 weeks for AZA to be therapeutically effective [5]. Of the patients who used AZA and were in clinical remission without treatment escalation at 14 weeks, half of the patients were no longer in clinical remission without treatment escalation to IFX at 52 weeks despite adequate AZA metabolites in the majority of the patients. This suggests that after achieving disease remission by conventional treatment in children with moderate-to-severe CD, AZA monotherapy is regularly insufficient to maintain sustained disease remission.

Although in multivariable analysis corticosteroid-treated patients had a higher odds ratio to achieve treatment success at 14 weeks compared to EEN treatment, this association was not found in relation to treatment escalation with IFX after 52 weeks. In line with prior meta-analysis [6, 28], no significant differences were found in remission rates at 52 weeks between patients treated with EEN induction and corticosteroid induction treatment.

One of the limitations of this cohort is the small sample size. Indeed, the TISKids study was not powered to identify potential associations with treatment success within the conventional treatment group. Studies including translational research with sufficient power to discriminate patients at baseline to establish a personalized treatment strategy would be beneficial to discriminate patients at diagnosis. Moreover, patients were not randomized between the EEN and corticosteroid group, as this was up to the patient and parents, in accordance with the treating physician. Selection bias could have occurred. However, SES-CD scores were comparable between the two groups at baseline suggesting this was not the case.

One of the strengths of this study was the quantity and quality of the data collection. Even though EEN and oral corticosteroids are frequently used to induce remission, only few studies [18, 19, 29] report endoscopic findings following induction treatment. Probably because the bowel preparation and general anaesthesia or deep sedation prior to endoscopy are stressful for paediatric patients [30].
may also explain why in our study not all children consented to the scheduled endoscopic evaluation which led to missing endoscopic data and a lower number of endoscopies.

In conclusion, children with moderate-to-severe newly diagnosed CD had low endoscopic remission rates without treatment escalation at 10 weeks after EEN or corticosteroid induction treatment bridging to AZA monotherapy. These results show, despite treatment according to recently updated guidelines, treatment targets often will not be achieved in children with moderate-to-severe CD. A personalized treatment strategy would be essential to achieve the target of endoscopic remission in these children. Our data suggest that patients with more severe inflammation are less likely to achieve clinical remission by EEN or corticosteroids, making them candidates for FL-1FX. Future studies are now ongoing [31] and are required to identify the specific patients who will benefit from EEN or corticosteroid induction treatment because patients should receive optimal effective treatment from diagnosis.

Supplementary Information The online version contains supplementary material available at https://doi.org/10.1007/s00431-022-04496-7.

Authors’ contributions LdR, MAC, and MMEJ contributed to the study concept and design. LdR, MMEJ, and SAV had full access to the data in the trial and take responsibility for the integrity of the data and the accuracy of the data analysis and contributed to drafting the manuscript. All the authors contributed to acquisition, analysis, or interpretation of the data. All the authors contributed to critical revision of the manuscript and provided important intellectual content. MMEJ contributed to the statistical analysis. LdR supervised the study. All the authors approved the final version of this manuscript.

Funding This investigator-initiated trial was financially supported by ZonMw (the Netherlands Organization for Health Research and Development) under project number 113202001, Crocokids (a Dutch fundraising organization to support research on IBD in children), and an Investigator-Sponsored Research Award from Pfizer (Study ID W1213008). The funders of the study had no role in the study design, data collection, statistical analysis, interpretation, or writing of the report. The corresponding author had full access to the data in the study and had final responsibility for the content of the manuscript and the decision to submit for publication. Infliximab (Inflectra) vials were provided by Pfizer for the first year after randomization.

Availability of data and material No data are available. The data that support the findings of this study are available from the corresponding author, upon reasonable request.

Code availability Not applicable.

Declarations

Ethics approval Medical-ethical approval was obtained for each site.

Consent to participate Informed consent was obtained from all individual participants included in the study.

Consent for publication Not applicable.

Competing interests LdR reports grants from ZonMW, ECCO, Crocokids, and Pfizer and consultancy fees from Abbvie, during the conduct of the study. MAC reports grants from ZonMw and Crocokids, and grants and non-financial support from Pfizer during the conduct of the study. IH received a payment/honourarium for lectures from BioGaia, Nutricia, Oktal pharma, Nestle, Biocodex, and Abelapharm. KLK received consultant fees from Abbvie, Biocodex, Ferring, MSD, and Tillotts Pharma, and research grants from the Pediatric Research Foundation (Finland) and the Helsinki University Research Fund, outside the submitted work. TH received a consultant fee from Pfizer, outside the submitted work. JS reports personal fees from Nutricia, outside the submitted work. MPvW reports personal fees from Danone and Laborie, outside the submitted work. ICE received consultant fees from Abbvie and Janssen, as well as research support from MSD and Nutricia. MMEJ, SAV, MpP, TGlDM, OFN, MG, VMW, HvW, CvdfE, PfE-R, STATR, MWJS, DR, and MD and JNS declare no competing interests.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Cucchiara S, Isoldi S, Nobili V (2019) Lesson from epidemiology of paediatric Crohn’s disease. Dig Liver Dis 51:503–504
2. Ghione S, Sarter H, Fumery M, Armengol-Debeir L, Savoye G, Ley D, Spyckerele C et al (2018) Dramatic increase in incidence of ulcerative colitis and Crohn’s disease (1988–2011): a population-based study of French adolescents. Am J Gastroenterol 113:265–272
3. Peyrin-Biroulet L, Sandborn W, Sands BE, Reinisch W, Bemelman W, Bryant RV, D’Haens G et al (2015) Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): determining therapeutic goals for treat-to-target. Am J Gastroenterol 110:1324–1338
4. Danese S, Fiorino G, Peyrin-Biroulet L (2017) Early intervention in Crohn’s disease: towards disease modification trials. Gut 66:2179–2187
5. van Rheezen PF, Aloj M, Assa A, Bronsky J, Escher JC, Fagerberg UL, Gasparetto M, Gerasimidis K, Griffiths A, Henderson P, Koletzko S, Kolho KL, Levine A, van Limbergen J, Martin de Carpi FJ, Navas-Lopez VM, Oliva S, de Ridder L, Russell RK, Shouval D, Spinelli A, Turner D, Wilson D, Wine E, Ruemmele FM (2020) The medical management of paediatric Crohn’s disease: an ECCO-ESPGHAN guideline update. J Crohns Colitis
6. Swaminath A, Feathers A, Ananthakrishnan AN, Falzon L, Li Ferry S (2017) Systematic review with meta-analysis: enteral nutrition therapy for the induction of remission in paediatric Crohn’s disease. Aliment Pharmacol Ther 46:465–456
7. Fell JM, Paintin M, Arnaud-Battandier F, Beattie RM, Hollis A, Kitching P, Donnet-Hughes A, MacDonald TT, Walker-Smith JA (2000) Mucosal healing and a fall in mucosal pro-inflammatory
cytokine mRNA induced by a specific oral polymeric diet in paediatric Crohn’s disease. Aliment Pharmacol Ther 14:281–289
8. Aljabeb F, Choonara I, Conroy S (2017) Systematic review of the toxicity of long-course oral corticosteroids in children. PLoS ONE 12:e0170259
9. Jongasma MME, Aardoom MA, Cozijnsen MA, van Pieterson M, de Meij T, Groeneweg M, Norbruus OF, Wolters VM, van Wering HM, Hojsak I, Kolho KL, Hummel T, Stapelbroek J, van der Feen C, van Rheezen PF, van Wijk MP, Teklenburg-Roord STA, Schreurs MJW, Rizopoulos D, Doukas M, Escher JC, Samson JN, de Ridder L (2020) First-line treatment with infliximab versus conventional treatment in children with newly diagnosed moderate-to-severe Crohn’s disease: an open-label multicentre randomised controlled trial. Gut
10. Cozijnsen MA, van Pieterson M, Samson JN, Escher JC, de Ridder L (2016) Top-down Infliximab Study in Kids with Crohn’s disease (TISKids): an international multicentre randomised controlled trial. BMJ Open Gastroenterol 3:e000123
11. Rueemmele FM, Veres G, Kolho KL, Griffiths A, Levine A, Escher JC, Amil Dias J et al (2014) Consensus guidelines of ECOO/ESPGHAN on the medical management of pediatric Crohn’s disease. J Crohns Colitis 8:1179–1207
12. Turner D, Griffiths AM, Walters TD, Seath T, Markowitz J, Pfefferkorn M, Keljo D, Waxman J, Otley A, LeLeiko NS, Mack D, Hyams J, Levine A (2012) Mathematical weighting of the pediatric Crohn’s disease activity index (PCDAI) and comparison with its other short versions. Inflamm Bowel Dis 18:55–62
13. Daperno M, D’Haens G, Van Assche G, Baert F, Bulois P, Maunoury V, Sostegni R, Rocca R, Pera A, Gevers A, Mary JY, Colombel JF, Rutgeerts P (2004) Development and validation of a new, simplified endoscopic activity score for Crohn’s disease: the SES-CD. Gastroin-test Endosc 60:505–512
14. Adler J, Gebremariam A, Eder SJ, French KR, Singer AA, Lewis JD, Sandberg KC, Picoraro JA, Moran CJ, Goyal A, Rosh J (2019) P083 validation of a new physician global assessment colono-scopy score (PGA-CS) for pediatric Crohn’s disease. Inflamm Bowel Dis 25:Page S39
15. De Ridder, L. Top-down Infliximab Study in Kids With Crohn’s Disease (TISKids). 2015 August 7 [last updated 2021 August 19]. In: ClinicalTrials.gov [Internet]. U.S. National Library of Medicine. Available from: https://clinicaltrials.gov/ct2/show/study/NCT02517684. ClinicalTrials.gov Identifier: NCT02517684
16. Hermanussen M, Cole J (2003) The calculation of target height reconsidered. Horm Res 59:180–183
17. Dutch Growth Research Foundation. Growth Analysers Research Calculation Tool [Internet]. Rotterdam, the Netherlands. Growth Analysers BV. Available from: https://growthanalysers.org/products/professional-use-research-calculation-tools-rect. Access date 25 March 2020
18. Borrelli O, Cordischi L, Cirulli M, Paganelli M, Labalestra V, Uccini S, Russo PM, Cucchiara S (2006) Polymeric diet alone versus corticosteroids in the treatment of active pediatric Crohn’s disease: a randomized controlled open-label trial. Clin Gastroenterol Hepatol 4:744–753
19. Berni Canani R, Terrin G, Borrelli O, Romano MT, Manguso F, Coruzzo A, D’Armiento F, Romeo EF, Cucchiara S (2006) Short- and long-term therapeutic efficacy of nutritional therapy and corticosteroids in paediatric Crohn’s disease. Dig Liver Dis 38:381–387
20. Grover Z, Burgess C, Muir R, Reilly C, Lewindon PJ (2016) Early mucosal healing with exclusive enteral nutrition is associated with improved outcomes in newly diagnosed children with luminal Crohn’s disease. J Crohns Colitis 10:1159–1164
21. Cohen-Dolev N, Sladek M, Hussey S, Turner D, Veres G, Koletzko S, Martin de Carpi J, Staiano A, Shaoul R, Lionetti P, Amil Dias J, Paerregaard A, Nuti F, Pfeffer Gik T, Ziv-Baran T, Ben Avraham Shulman S, Sarbagili Shabat C, Sigall Boneh R, Russell RK, Levine A (2018) Differences in outcomes over time with exclusive enteral nutrition compared with steroids in children with mild to moderate Crohn’s disease: results from the GROWTH CD study. J Crohns Colitis 12:306–312
22. Pigneur B, Lepage P, Mondot S, Schmitz J, Goulet O, Dore J, Rueemmele FM (2019) Mucosal healing and bacterial composition in response to enteral nutrition vs steroid-based induction therapy—a randomised prospective clinical trial in children with Crohn’s disease. J Crohns Colitis 13:846–855
23. Oliva S, Thomson M, de Ridder L, Martin-de-Carpi J, Van Biervliet S, Braegger C, Dias JA, Kolacke S, Miele E, Baderus S, Bronsky J, Winter H, Navas-López VM, Assa A, Chong SKF, Afzal NA, Smets F, Shaoul R, Hussey S, Turner D, Cucchiara S (2018) Endoscopy in pediatric inflammatory bowel disease: a position paper on behalf of the Porto BDG Group of the European Society for Pediatric Gastro-enterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr 67:414–430
24. Logan M, Clark CM, Ijaz UZ, Gervais L, Duncan H, Garrick V, Curtis L, Buchanan E, Cardigan T, Armstrong L, Delahunty C, Flynn DM, Barclay AR, Taylor R, McDonald E, Milling S, Hansen RK, Gerasimidis K, Russell RK (2019) The reduction of faecal calprotectin during exclusive enteral nutrition is lost rapidly after food re-introduction. Aliment Pharmacol Ther 50:664–674
25. Miller T, Suskind DL (2018) Exclusive enteral nutrition in pedi-atric inflammatory bowel disease. Curr Opin Pediatr 30:671–676
26. Grover Z, Lewindon P (2015) Two-year outcomes after exclusive enteral nutrition induction are superior to corticosteroids in paediatric Crohn’s disease treated early with thiopurines. Dig Dis Sci 60:3069–3074
27. Ricciuto A, Aardoom M, Orlanski-Meyer E, Navon D, Carman N, Aloi M, Bronsky J, Däbritz J, Dubinsky M, Hussey S, Lewindon P, Martin De Carpi J, Navas-López VM, Orsi M, Rueemmele FM, Russell RK, Veres G, Walters TD, Wilson DC, Kaiser T, de Ridder L, Turner D, Griffiths AM, Steering Committee (2021) Predicting outcomes in pediatric Crohn’s disease for management optimization: systematic review and consensus statements from the Pediatric Inflammatory Bowel Disease-Ahead Program. Gastroenterology 160(403–436):e426
28. Drzżecichar P, Horvath A, Shamir R, Szajewska H (2007) Meta-analysis: enteral nutrition in active Crohn’s disease in children. Aliment Pharmacol Ther 26:795–806
29. Grover Z, Muir R, Lewindon P (2014) Exclusive enteral nutrition induces early clinical, mucosal and transmural remission in paediatric Crohn’s disease. J Gastroenterol 49:638–645
30. Turner D, Griffiths AM, Wilson D, Mould DR, Baldassano RN, Russell RK, Dubinsky M, Heyman MB, de Ridder L, Hyams J, Martin de Carpi J, Conklin L, Faubion WA, Koletzko S, Bousvaros A, Rueemmele FM (2019) Designing clinical trials in paediatric inflammatory bowel diseases: a PIBDnet commentary. Gut
31. Harris RE, Aloi M, de Ridder L, Croft NM, Koletzko S, Levine A, Sladek M, Turner D, Veereman G, Neyt M, Bigot L, Ruemmele FM (2020) Protocol for a multinational risk-stratified randomised controlled trial in paediatric Crohn’s disease: methotrexate versus adalimumab or adalimumab for maintaining remission in patients at low or high risk for aggressive disease course. BMJ Open 10:e034892

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Authors and Affiliations

Maria M. E. Jongsma1 · Stephanie A. Vuijk1 · Martinus A. Cozijnsen1 · Merel van Pieterson1 · Obbe F. Norbruis2 · Michael Groeneweg3 · Victorien M. Wolters4 · Herbert M. van Wering5 · Iva Hojsak6 · Kaija-Leena Kolho7,8 · Michiel P. van Wijk9 · Sarah T. A. Teklenburg-Roord2 · Tim G. J. de Meij9 · Johanna C. Escher1 · Lissy de Ridder1

Maria M. E. Jongsma
m.jongsma@erasmusmc.nl
Stephanie A. Vuijk
s.a.vuijk@erasmusmc.nl
Martinus A. Cozijnsen
cozijnsen@dhd.nl
Merel van Pieterson
m.vanpieterson@erasmusmc.nl
Obbe F. Norbruis
o.f.norbruis@isala.nl
Michael Groeneweg
groenewegM@maasstadziekenhuis.nl
Victorien M. Wolters
v.m.wolters@umcutrecht.nl
Herbert M. van Wering
hvanwering@amphia.nl
Iva Hojsak
ivahojsak@gmail.com
Kaija-Leena Kolho
kaija-leena.kolho@helsinki.fi
Michiel P. van Wijk
m.vanwijk@amsterdamumc.nl
Sarah T. A. Teklenburg-Roord
s.t.a.teklenburgroord@isala.nl
Tim G. J. de Meij
t.demeij@amsterdamumc.nl
Johanna C. Escher
j.escher@erasmusmc.nl

1 Department of Pediatric Gastroenterology, Erasmus Medical Centre-Sophia Children’s Hospital, Room SP-2430, P.O. Box 2040, 3000 Rotterdam, CA, Netherlands
2 Department of Pediatric Gastroenterology, Isala Hospital, Zwolle, Netherlands
3 Department of Pediatric Gastroenterology, Maasstad Hospital, Rotterdam, Netherlands
4 Department of Pediatric Gastroenterology, Utrecht Medical Centre-Wilhelmina Children’s Hospital, Utrecht, Netherlands
5 Department of Pediatric Gastroenterology, Amphia Hospital, Breda, Netherlands
6 Referral Centre for Pediatric Gastroenterology and Nutrition, Children’s Hospital Zagreb, University of Zagreb Medical School, Zagreb, Croatia
7 Tampere University Hospital and University of Tampere, Tampere, Finland
8 Children’s Hospital, University of Helsinki, Helsinki, Finland
9 Department of Pediatric Gastroenterology, Amsterdam UMC-Emma Children’s Hospital, VU University, Amsterdam, Netherlands